1-4 of 4
Susan Erickson-Viitanen
Close
Sort by
Journal Articles

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

Srdan Verstovsek, MD, PhD, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, MD, Vikas Gupta, MD, FRCP, FRCPath, John F. DiPersio, MD, PhD, John V. Catalano, MD, Michael W.N. Deininger, MD, PhD, Carole B. Miller, MD, Richard T. Silver, MD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Murat O. Arcasoy, MD, Elizabeth O. Hexner, MD, Roger M. Lyons, MD, Ronald Paquette, MD, PhD, Azra Raza, MD, Kris Vaddi, PhD, Susan Erickson-Viitanen, PhD, William Sun, PhD, Victor A. Sandor, MD, CM, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2012) 120 (21): 800.
https://doi.org/10.1182/blood.V120.21.800.800
Published: 2012
Journal Articles

Long-Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety.

Srdan Verstovsek, MD, PhD, Hagop Kantarjian, MD, Ruben A. Mesa, MD, Jorge Cortes-Franco, MD, Animesh D. Pardanani, MBBS, PhD, Deborah A. Thomas, MD, Zeev Estrov, MD, Edward C Bradley, MD, Susan Erickson-Viitanen, PhD, Kris Vaddi, Ph.D., Richard Levy, MD, Ayalew Tefferi, MD
Journal: Blood
Blood (2009) 114 (22): 756.
https://doi.org/10.1182/blood.V114.22.756.756
Published: 2009
Journal Articles

Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial.

Ruben A. Mesa, MD, Hagop Kantarjian, Ayalew Tefferi, MD, Richard Levy, MD, Kris Vaddi, Susan Erickson-Viitanen, PhD, Deborah A. Thomas, MD, Jorge Cortes-Franco, MD, Gautam Borthakur, MBBS, Animesh D. Pardanani, MBBS, PhD, Zeev Estrov, MD, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3917.
https://doi.org/10.1182/blood.V114.22.3917.3917
Published: 2009
Journal Articles

INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF).

Ruben A. Mesa, MD, FACP, Srdan Verstovsek, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Steven Friedman, MD, Robert Newton, Susan Erickson-Viitanen, Deborah Hunter, John Redman, MD, Swamy Yeleswaram, Edward Bradley, MD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 1760.
https://doi.org/10.1182/blood.V112.11.1760.1760
Published: 2008